Hepatocellular carcinoma

Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020

Retrieved on: 
Tuesday, January 21, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Cancer, Chloroarenes, Pyridines, Ureas, Regorafenib, Bayer, Gastrointestinal cancer, Larotrectinib, Hepatocellular carcinoma, Brachyury, Vitrakvi® (larotrectinib), Stivarga® (regorafenib), Oncology at Bayer, Bayer

Bayer will present new research from the Companys oncology portfolio, including Stivarga (regorafenib) and Vitrakvi (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California.

Key Points: 
  • Bayer will present new research from the Companys oncology portfolio, including Stivarga (regorafenib) and Vitrakvi (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California.
  • The presentations will feature data on Stivarga in hepatocellular carcinoma (HCC) and gastric and colorectal cancers, as well as Vitrakvi in gastrointestinal cancer.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.
  • For more information, go to www.bayer.com
    BAYER, the Bayer Cross, Vitrakvi, and Stivarga are registered trademarks of Bayer.

TriSalus™ Life Sciences Launches the new TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers within Solid Tumors

Retrieved on: 
Monday, January 13, 2020
Biotechnology, Medical devices, Health, Pharmaceutical, Oncology, Medicine, Medical specialties, Cancer, Hepatology, Oncology, Hepatocellular carcinoma, Tumor microenvironment, Metástasis, Brachyury, Ultrasonography of liver tumors

TriSalusTM Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav Infusion System (TriNav).

Key Points: 
  • TriSalusTM Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav Infusion System (TriNav).
  • Powered by its proprietary Pressure-Enabled Drug DeliveryTM (PEDD) approach with SmartValveTM technology, TriNav is designed to help overcome the infusion barriers that limit therapeutic uptake in solid tumors, including hepatocellular carcinoma (HCC) and liver metastases.2,3
    This press release features multimedia.
  • It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.15
    TriSalusTM Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors.
  • This innovative approach has the potential to allow for the administration of multiple mechanisms that can work together to overcome inherent immune suppression within the solid tumor microenvironment.

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

Retrieved on: 
Wednesday, January 8, 2020
Medicine, Health, Clinical medicine, Cancer treatments, Sintilimab, Therapy, Hepatocellular carcinoma, Combination therapy, Cancer

Developing a combination therapy, comprised of an antibody drug and a RNAi drug, may provide more comprehensive and effective treatments for patients.

Key Points: 
  • Developing a combination therapy, comprised of an antibody drug and a RNAi drug, may provide more comprehensive and effective treatments for patients.
  • The potential clinical value of the combination therapy of sintilimab and cotsiranib will be evaluated and wehope more patients will benefit from this potential therapy globally."
  • Michael Molyneaux, MD, Chief Medical Officer of Sirnaomics, stated, "Sirnaomics is very excited to enter into this collaboration agreement with Innovent to potentially bring lifesaving therapies to patients with Hepatocellular Cancers.
  • Innovent is also conducting clinical studies of sintilimab injection in the United States.

Aligos Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 7, 2020
Medical specialties, Medicine, Clinical medicine, Infectious causes of cancer, Hepatitis, RTT, Healthcare-associated infections, Hepatology, Hepatocellular carcinoma, Liver disease, Steatohepatitis, Viral hepatitis

A webcast of the presentation will be available within 24 hours of the presentation and will remain available for 30 days at the following link: https://jpmorgan.metameetings.net/events/hc20/sessions/30482-aligos-ther...

Key Points: 
  • A webcast of the presentation will be available within 24 hours of the presentation and will remain available for 30 days at the following link: https://jpmorgan.metameetings.net/events/hc20/sessions/30482-aligos-ther...
    Aligos Therapeutics, Inc. is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases.
  • Aligos is focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), which collectively affect hundreds of millions of people across the world.
  • Aligos strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of best-in-class molecules.
  • Please visit www.aligos.com for more information.

Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

Retrieved on: 
Tuesday, January 7, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Medicine, Liver, RTT, Hepatitis, Hepatology, Steatohepatitis, Fatty liver disease, Non-alcoholic fatty liver disease, Hepatocellular carcinoma, Liver cancer, Liver disease, Namodenoson, Can-Fite BioPharma Ltd.

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).

Key Points: 
  • Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).
  • Namodenoson is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned Phase III trial in this indication.
  • The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
  • Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH).

Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019

Retrieved on: 
Thursday, December 12, 2019
Cancer, Medicine, Medical specialties, Infectious causes of cancer, Hepatology, Uveal melanoma, Melanoma, Hepatocellular carcinoma, Neuroendocrine tumor, Metástasis, Delcath Systems, DecisionDx-UM

PV-10 is administered percutaneously when targeting primary or metastatic tumors of the liver, such as hepatocellular carcinoma (HCC), metastatic colorectal cancer, metastatic neuroendocrine tumors, and metastatic uveal melanoma (mUM).

Key Points: 
  • PV-10 is administered percutaneously when targeting primary or metastatic tumors of the liver, such as hepatocellular carcinoma (HCC), metastatic colorectal cancer, metastatic neuroendocrine tumors, and metastatic uveal melanoma (mUM).
  • Preliminary Metastatic Uveal Melanoma Results from the Presentation at ESMO I-O Congress 2019:
    Baseline characteristics (N=13): 46% men; median age of 61 years; 46% elevated LDH.
  • Treatment summary: 7 patients received 1 cycle of PV-10; 6 patients received 2 cycles; 26 tumors were injected with PV-10.
  • PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver (including metastatic neuroendocrine tumors and metastatic uveal melanoma).

Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma

Retrieved on: 
Wednesday, December 4, 2019
Medical specialties, Health, Drugs, Antiemetics, Appetite stimulants, Aromatase inhibitors, Entheogens, Euphoriants, Tetrahydrocannabinol, Hepatocellular carcinoma, Cannabinoid, Orphan drug

OTTAWA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (Tetra or the Company) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.

Key Points: 
  • OTTAWA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (Tetra or the Company) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.
  • We are very pleased to have received Orphan Drug Designation (ODD) from the FDA for THC.
  • This second ODD for cannabinoids demonstrates our innovation and successful drug development program that will soon include hepatocellular carcinoma," said Dr.
  • We intend to bring a modified formulation of Caumzfor hepatocellular carcinoma into clinical trials in Q1 2020.

Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019

Retrieved on: 
Tuesday, December 3, 2019
Medical specialties, Medicine, Cancer, RTT, Infectious causes of cancer, Hepatology, Interventional oncology, Hepatocellular carcinoma, Oncology, Metástasis, Delcath Systems

The LD Micro Main Event will take place on December 10-12, 2019 in Los Angeles at the Luxe Sunset Bel Air Hotel.

Key Points: 
  • The LD Micro Main Event will take place on December 10-12, 2019 in Los Angeles at the Luxe Sunset Bel Air Hotel.
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
  • LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

Aligos Therapeutics Welcomes Kathleen Sereda Glaub to its Board of Directors

Retrieved on: 
Monday, November 25, 2019
Medical specialties, Medicine, Clinical medicine, Hepatology, RTT, Hepatocellular carcinoma, Hepatitis, Steatohepatitis

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced the appointment of Kathleen Sereda Glaub to the companys board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced the appointment of Kathleen Sereda Glaub to the companys board of directors.
  • She currently serves as executive chair of the board of directors at CuraSen Therapeutics, which she also co-founded, and as board director of Escient Pharmaceuticals and IO Biotech.
  • With her extensive experience, we welcome Ms. Glaub to the board.
  • Aligos presents a wonderful opportunity in the form of a differentiated and diversified asset portfolio assembled by a seasoned management team.

Genentech Presents Pivotal Data Demonstrating Tecentriq in Combination With Avastin Improves Overall Survival in People With the Most Common Form of Liver Cancer

Retrieved on: 
Friday, November 22, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, RTT, Genentech, Hepatology, Cancer treatments, Orphan drugs, Atezolizumab, Liver cancer, Bevacizumab, Sorafenib, Hepatocellular carcinoma, the IMbrave150 study, hepatocellular carcinoma, the Tecentriq and Avastin combination, Tecentriq® (atezolizumab), Avastin® (bevacizumab), Genentech in personalized cancer immunotherapy, Genentech

Grade 3-4 adverse events (AEs) occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib.

Key Points: 
  • Grade 3-4 adverse events (AEs) occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib.
  • According to the American Cancer Society, it is estimated that more than 42,000 Americans will be diagnosed with liver cancer in 2019.
  • HCC accounts for approximately 75% of all liver cancer cases in the United States.
  • There is a strong scientific rationale to support further investigation of Tecentriq plus Avastin in combination.